Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
Sponsored by Kaiser Permanente
About this trial
Last updated 2 years ago
Study ID
CN-18-3176
Status
Completed
Type
Observational
Placebo
No
Accepting
18 to 64 Years
All
Trial Timing
Ended 2 years ago
What is this trial about?
The overall objective of this study is to describe the effectiveness of Flublok
Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in
adults 18 through 64 years of age. During this study, Flublok Quadrivalent or SD-IIV will
be administered according to the guidelines in the Prescribing Information materials and
only to persons for whom it is indicated. The 2018-2019, 2019-2020, and 2020-2021
formulations of recombinant influenza vaccine (Flublok Quadrivalent vaccine) and SD-IIV
will be evaluated for outcomes including all polymerase chain reaction (PCR)-confirmed
influenza, PCR-confirmed hospitalized influenza, hospitalized community-acquired
pneumonia and cardio-respiratory events.
What are the participation requirements?
Inclusion Criteria
- Between the ages of ≥18 and <65 years at the time of influenza vaccination
- Receive either Flublok Quadrivalent vaccine or standard dose inactivated influenza vaccine at a Kaiser Permanente Northern California facility during the study period from August 2018 through April 2020
Exclusion Criteria
- Children <18 years old
- Adults ≥65 years old